Loading data
BIONYSE
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.58 bn USD | 2.57 bn USD | 2.67 bn USD | 2.8 bn USD | 2.92 bn USD |
| Cost of revenue | 1.24 bn USD | 1.19 bn USD | 1.24 bn USD | 1.23 bn USD | 1.28 bn USD |
| Gross profit | 1.34 bn USD | 1.38 bn USD | 1.43 bn USD | 1.57 bn USD | 1.64 bn USD |
| Research and development expense | 275.6 m USD | 295.9 m USD | 247.4 m USD | 256.9 m USD | 260.64 m USD |
| Selling, general and administrative expense | 844.3 m USD | 814 m USD | 841.7 m USD | 827.8 m USD | 877.12 m USD |
| Operating profit | 47.2 m USD | 269 m USD | 337.8 m USD | 482.6 m USD | 500.34 m USD |
| Interest expense | 49 m USD | 48.9 m USD | 49.4 m USD | 38.1 m USD | 1.55 m USD |
| Profit before tax | 995.5 m USD | -2.34 bn USD | -850.1 m USD | -4.7 bn USD | 5.45 bn USD |
| Income tax expense | 235.6 m USD | -498.3 m USD | -212.8 m USD | -1.08 bn USD | 1.19 bn USD |
| Net income (reported basis) | 759.91 m USD | -1.84 bn USD | -637.32 m USD | -3.63 bn USD | 4.25 bn USD |
| Basic earnings per share | 27.87 USD/share | -65.36 USD/share | -21.82 USD/share | -121.79 USD/share | 142.61 USD/share |
| Diluted earnings per share | 27.85 USD/share | -65.36 USD/share | -21.82 USD/share | -121.79 USD/share | 140.83 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.